本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002864 证券简称：盘龙药业 公告编号：2026-006 陕西盘龙药业集团股份有限公司 关于公司获得药物临床试验批准通知书的公告 近日，陕西盘龙药业集团股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，同意酮洛芬凝胶贴膏开展 临床试验。现将有关情况公告如下： 一、药品相关情况 产品名称：酮洛芬凝胶贴膏 公司本次申请药物临床试验的酮洛芬凝胶贴膏，规格：每贴（14cm×10cm）， 含膏体 10g，含酮洛芬 30mg。其适应症为适用于下列疾病和症状的镇痛、消炎： 骨关节炎、肩周炎、肌腱炎、腱鞘周围炎、肱骨外上髁炎（网球肘）、肌肉痛、 外伤所致肿胀、疼痛。给药方式为局部贴敷，每次一贴，一日 2 次。注册分类属 化学药品 3 类。 酮洛芬凝胶贴膏最早于 1988 年由久光制药株式会社在日本上市，截至本公 告披露日，酮洛芬凝胶贴膏的原研药尚未在国内上市，国内仅湖南九典制药股份 有限公司获国家药品监督管理局批准上市。 1 申请事项：药物临床试验 通知书编号：2026L ...

Core Viewpoint - Panlong Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Ketoprofen gel patch, which is intended for pain relief in various conditions [1] Group 1: Product Details - The approved drug is a Ketoprofen gel patch, classified as a Class 3 chemical drug [1] - The patch is designed for local application, with a size of 14cm x 10cm, containing 10g of gel and 30mg of Ketoprofen [1] - Indications for the drug include osteoarthritis, periarthritis of the shoulder, tendonitis, tenosynovitis, lateral epicondylitis (tennis elbow), muscle pain, and swelling and pain due to trauma [1] Group 2: Regulatory Approval - The clinical trial approval notification number is 2026LP00383 [1] - The approval allows the company to conduct clinical trials aimed at pain relief [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of Ketoprofen Gel Patch, indicating progress in its product development pipeline [1] Group 1: Product Details - The Ketoprofen Gel Patch is specified to be 14cm x 10cm in size, containing 10g of gel and 30mg of Ketoprofen [1] - The indications for the product include pain relief and anti-inflammatory treatment for conditions such as osteoarthritis, periarthritis of the shoulder, tendinitis, de Quervain's tenosynovitis, lateral epicondylitis (tennis elbow), muscle pain, and swelling and pain due to trauma [1] - The administration method is local application, with one patch applied twice daily [1] Group 2: Regulatory Classification - The product is classified as a Class 3 chemical drug according to registration standards [1]

Summary of Key Points from Conference Call Records Industry Overview 1. PCB (Printed Circuit Board) - The PCB sector has shown weak performance since Q4 of last year, primarily due to divergent market views on orthogonal backplane solutions, with some believing they may be replaced by copper cables/CPO or delayed until 2028. However, the orthogonal backplane is currently progressing steadily and is expected to enter mass production in H2 2027. Leading companies are experiencing stock price stagnation due to these divergences, highlighting their cost-effectiveness. Recommended companies include Dongshan Precision, Shenghong Technology, and Huidian Co. [1] - The CoWoP (Chip on Wafer on PCB) solution has stronger certainty, can reduce costs, improve efficiency, and bypass the shortage of substrate capacity. The value per square meter of PCB may increase several times, potentially reaching tenfold, with product launches expected by the end of 2027 and full implementation in 2028. Recommended companies in this direction include Pengding Holdings, Shennan Circuit, and Xinsong Technology. [1] 2. Storage - Contract prices remain in an upward cycle despite fluctuations in spot prices. Module companies are expected to see explosive Q1 performance, with Jiangbolong and Demingli realizing low-priced inventory. Recommended design companies include Zhaoyi Innovation (with a profit expectation of 6 billion) and Puran Co., Beijing Junzheng, and Hengshuo Co. [2] - Demand for memory modules is driven by AI servers and general servers, with recommendations for Lanke Technology (long-term profit of 10 billion) and Jucheng Co. (long-term profit of 1.5 billion). [2] 3. Communication - The recent decline in optical modules is related to the pullback of US tech stocks and speculation around CPO concepts. However, industry sources (such as Coherent and Xuchuang) indicate that CPO's potential to replace optical modules in ScaleOut scenarios is low, suggesting that short-term speculation may be excessive. [2] - North American cloud service providers have exceeded capital expenditure guidance for 2026 (620 billion, up 65% year-on-year), indicating potential accelerated demand for optical modules in 2027. Key upcoming catalysts include Nvidia's quarterly report (February 26), GTC conference (March), and OFC exhibition (NPO product showcase). Recommended companies include Zhongji Xuchuang, Xinyisheng, and Dongshan Precision. [2] - For copper connections as a Plan B alternative to orthogonal backplanes, companies to watch include Luxshare Precision, Wokai Nuclear Materials, and Huiju Technology (with potential for stock doubling). [2] - The price of scattered fiber has surged in the short term (from 25 to 50 yuan), but the low willingness of operators to raise prices raises doubts about long-term sustainability. [2] 4. Computing - Domestic computing resources are in short supply, with the recent downtime of Qianwen highlighting the scarcity of AI foundational resources. The demand for CPUs is expected to rise due to increased usage of agents compared to chatbots. Recommended companies include Haiguang Information (benefiting from both CPU and GPU), Cambrian (leading domestic AI chip manufacturer), and Tianshu Zhixin (expected to accelerate integration with leading players). [2] - Cloud infrastructure resources are expected to benefit from price increases, with recommendations for Kingsoft Cloud, Wangsu Technology, and Fourth Paradigm. [2] - In the AI application sector, the recent drop in overseas software and restructuring of SaaS business models may lead to a narrative reversal with the launch of native agent products in Q3 2026. Companies to watch include Alibaba for 2C entry reconstruction and third-party AI agents like TaxFriend, Zhongkong Technology, and Dingjie Smart. [2] 5. Media - Tencent has faced a decline due to market concerns over potential tax increases on internet platforms, although there is no space for increased game value-added tax. The company remains recommended despite rumors of Q4 earnings downgrades, maintaining a PE ratio of 15 times, which still offers value. [3] - The download situation for the Yuanbao app remains stable, and Tencent's AI capabilities may be closing the gap with larger competitors. [3] - In gaming, companies with upcoming catalysts such as Giant Network and Perfect World are recommended for short-term focus, while Century Huatong and Kaiying Network are suggested for medium to long-term attention due to expected catalysts. [3] - Tencent's establishment of a separate AI comic app is beneficial for the production side, which is entering a period of profitability. Recommendations include Kuaishou, Huanrui, and Rongxin. [3] 6. Pharmaceuticals - Attention is drawn to the update of the essential drug catalog, which may accelerate progress. [4] - The probability of inclusion in the essential drug catalog is high for unique products, with several specific products from companies like Jichuan Pharmaceutical and Panlong Pharmaceutical being highlighted. [4] - Emphasis on the global competitiveness of the innovative drug industry chain, with a focus on new-generation ADCs, IOs, small nucleic acids, and CGT. Recommended companies include Kanghong, Yingen, Yunding, and Chengdu Xian Dao. [4] - The brain-computer interface theme is noted, with a potential showcase of non-invasive products during the Spring Festival and a semi-invasive product approval for Borui Kang in March. [4] - Recommendations include Meihua Medical, Dongwei Semiconductor, and Sanbo Brain Science. [5] - The surgical robot sector is expected to see comprehensive implementation of charging policies before August, with overseas orders doubling and maintaining high growth in 2027. Key types include laparoscopic and orthopedic robots, with strong overseas performance for laparoscopic robots. Recommended companies include MicroPort, Jingfeng Medical, Tianzhihang, and Sanyou Medical. [6]

Fundraising Overview - The company issued 9,352,740 shares of common stock at a price of RMB 32.29 per share, raising a total of RMB 301,999,974.60 [1] - After deducting underwriting fees and other related expenses, the net amount raised was RMB 294,836,292.23 [1] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure efficient use of funds and protect investor rights [2] - A tripartite supervision agreement was signed with the sponsor and banks to manage the raised funds [2] Fund Account Closure - The account used for the "Traditional Chinese Medicine Formula Granule R&D and Industrialization Project" was closed on February 4, 2026, after the funds were permanently transferred to working capital, leaving a balance of RMB 0.00 [2]

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index up by 0.11%, the Shenzhen Component Index up by 0.65%, and the ChiNext Index also up by 0.65% as of midday [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day, with over 3,800 stocks rising [2] Sector Performance - Active sectors included lithium batteries, energy metals, humanoid robots, and fintech, while traditional sectors like liquor, retail, and AI application stocks weakened [1] - The Chinese medicine and chemical sectors showed notable gains, with the Chinese medicine sector rising by 2.52% [2][7] - The small metals sector rebounded, with stocks like Xianglu Tungsten and Zhangyuan Tungsten hitting the daily limit [7] Notable Stocks - Mingdiao Co. experienced significant trading activity, achieving a "limit-up" with nearly 700 million yuan in transactions and marking its fifth consecutive trading day of gains [3] - Jiangfeng Electronics saw a slight increase of 0.09% after announcing plans to acquire control of Kaide Quartz [9] Economic Indicators - The industrial development plan for traditional Chinese medicine aims for a collaborative development system by 2030, which may positively impact the sector [7]

Market Overview - A-shares showed resilience against external market pressures, with major indices recovering after a low opening, resulting in the Shanghai Composite Index rising by 4.40 points (0.11%) to 4080.31 points, the Shenzhen Component Index increasing by 90.46 points (0.65%) to 14043.17 points, and the ChiNext Index up by 21.17 points (0.65%) to 3281.45 points [1] Sector Performance - The chemical sector saw strong performance, with stocks like Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [1] - The humanoid robot concept stocks were active, with companies such as Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. also reaching the daily limit [1] - The non-ferrous metals sector showed signs of recovery, with Hunan Gold and Xianglu Tungsten hitting the daily limit [1] - The traditional Chinese medicine sector opened strong, with stocks like Te Yi Pharmaceutical reaching the daily limit [1] Policy Support - The Chinese government, through the Ministry of Industry and Information Technology and other departments, issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030, which is expected to boost the sector's growth [2] Price Dynamics - The price of disperse dyes surged due to a significant increase in the cost of upstream key intermediates, rising from 25,000 yuan/ton to 38,000 yuan/ton, a more than 50% increase, which is expected to drive up prices in the textile dyeing industry as demand increases post-Spring Festival [3] Market Challenges - The liquor sector faced downward pressure, with stocks like Huangtai Liquor hitting the daily limit down, attributed to a decline in demand following the consumption peak around the Spring Festival and increased competition leading to price cuts [4] - AI application stocks experienced declines, with companies like Yaowang Technology and Zhejiang Wenhu falling to the daily limit due to concerns over technology maturity and unclear business models [5] - The optical module and CPO sectors continued to adjust, with stocks like Yuanjie Technology and Xinyisheng dropping over 6% as market expectations normalized [6] Institutional Insights - Zhongjin Securities noted that despite external pressures, there are no typical bull market top signals in Chinese stocks, with ample liquidity and improving earnings, suggesting a continued positive outlook for Chinese asset revaluation [7] - Tianfeng Securities highlighted the fragility of market sentiment, indicating that any news could trigger short-term sell-offs, particularly in the gold market [7] - Huachuang Securities observed a strong recovery in consumer markets expected for the 2026 Spring Festival, driven by government-led consumption initiatives, suggesting potential growth in sectors like dining, tourism, and retail [7]

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Fundraising Overview - The company raised a total of RMB 301,999,974.60 by issuing 9,352,740 shares at a price of RMB 32.29 per share on September 19, 2023 [1] - After deducting underwriting fees and other related expenses, the net amount raised was RMB 294,836,292.23 [1] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure efficient use of funds and protect investor rights [3] - A tripartite supervision agreement was signed with the sponsor and banks to manage the raised funds [3] Account Closure - The account used for the "Traditional Chinese Medicine Formula Granule R&D and Industrialization Project" was closed on February 4, 2026, as the balance was zero after funds were permanently transferred to working capital [3]

Core Viewpoint - The company announced a private placement of 9.35 million shares at a price of 32.29 yuan per share, raising a total of 302 million yuan, with a net amount of 295 million yuan [1] Group 1: Fundraising Details - The company signed a tripartite supervision agreement with the sponsoring institution and related banks regarding the raised funds [1] - The funds are designated for the "Research and Industrialization Project of Traditional Chinese Medicine Formula Granules" [1] Group 2: Account Status - As of the announcement date, the account at Bank of China Xi'an Software Park Branch for the project has a zero balance and will be closed in 2026, with the corresponding supervision agreement also terminating [1]